These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16627040)

  • 1. Effects of levonorgestrel-releasing intrauterine system on glucose and lipid metabolism: a 1-year follow-up study.
    Kayikcioglu F; Gunes M; Ozdegirmenci O; Haberal A
    Contraception; 2006 May; 73(5):528-31. PubMed ID: 16627040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Mirena (levonorgestrel-releasing intrauterine system) and Ortho Gynae T380 intrauterine copper device on lipid metabolism--a randomized comparative study.
    Ng YW; Liang S; Singh K
    Contraception; 2009 Jan; 79(1):24-8. PubMed ID: 19041437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel.
    Skouby SO; Endrikat J; Düsterberg B; Schmidt W; Gerlinger C; Wessel J; Goldstein H; Jespersen J
    Contraception; 2005 Feb; 71(2):111-7. PubMed ID: 15707560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of etonogestrel implant on serum lipids, liver function tests and hemoglobin levels.
    Dilbaz B; Ozdegirmenci O; Caliskan E; Dilbaz S; Haberal A
    Contraception; 2010 Jun; 81(6):510-4. PubMed ID: 20472118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue.
    Ferreira RA; Vieira CS; Rosa-E-Silva JC; Rosa-e-Silva AC; Nogueira AA; Ferriani RA
    Contraception; 2010 Feb; 81(2):117-22. PubMed ID: 20103448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of levonorgestrel-releasing intrauterine system on serum lipids and hepatic function].
    He SM
    Di Yi Jun Yi Da Xue Xue Bao; 2005 Oct; 25(10):1321-2, 1324. PubMed ID: 16234121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of the levonorgestrel intrauterine system on uterine artery blood flow 1 year after insertion.
    Haberal A; Kayikcioglu F; Gunes M; Kaplan M; Ozdegirmenci O
    Ultrasound Obstet Gynecol; 2006 Mar; 27(3):316-9. PubMed ID: 16450358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of levonorgestrel intrauterine system on uterine myomas: a 1-year follow-up study.
    Gunes M; Ozdegirmenci O; Kayikcioglu F; Haberal A; Kaplan M
    J Minim Invasive Gynecol; 2008; 15(6):735-8. PubMed ID: 18971138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
    Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
    Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
    Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of menorrhagia with the levonorgestrel releasing intrauterine system: effects on ovarian function and uterus.
    Tasci Y; Caglar GS; Kayikcioglu F; Cengiz H; Yagci B; Gunes M
    Arch Gynecol Obstet; 2009 Jul; 280(1):39-42. PubMed ID: 19066923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
    Zheng LY; Pan JQ; Lv JH
    Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
    Magalhães J; Aldrighi JM; de Lima GR
    Contraception; 2007 Mar; 75(3):193-8. PubMed ID: 17303488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients.
    Fideleff HL; Boquete HR; Stalldecker G; Giaccio AV; Sobrado PG
    Growth Horm IGF Res; 2008 Aug; 18(4):318-24. PubMed ID: 18289903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia.
    Kostapanos MS; Milionis HJ; Filippatos TD; Nakou ES; Bairaktari ET; Tselepis AD; Elisaf MS
    Clin Ther; 2007 Jul; 29(7):1403-14. PubMed ID: 17825691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.
    Lehtovirta P; Paavonen J; Heikinheimo O
    Contraception; 2007 Jan; 75(1):37-9. PubMed ID: 17161122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The levonorgestrel intrauterine system (Mirena) for treatment of idiopathic menorrhagia. Assessment of quality of life and satisfaction.
    Lete I; Obispo C; Izaguirre F; Orte T; Rivero B; Cornellana MJ; Bermejo I;
    Eur J Contracept Reprod Health Care; 2008 Sep; 13(3):231-7. PubMed ID: 18609346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrauterine or oral administration of levonorgestrel in combination with estradiol to perimenopausal women--effects on lipid metabolism during 12 months of treatment.
    Andersson K; Stadberg E; Mattsson LA; Rybo G; Samsioe G
    Int J Fertil Menopausal Stud; 1996; 41(5):476-83. PubMed ID: 8934257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.